Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to accelerate oncology drug discovery and development, has announced its financial results and business updates for the third quarter of 2025, ending September 30, 2025. The quarter marked a pivotal period for the company, highlighted by the successful completion of enrollment in the LP-184 Phase 1a clinical trial, which met all primary endpoints. The trial, involving 63 patients, demonstrated a 48% clinical benefit rate at or above the therapeutic dose threshold across multiple hard-to-treat solid tumors, along with a favorable safety profile and strong biomarker signals. These results validate Lantern’s AI-driven precision medicine approach and support the advancement of LP-184 into planned Phase 1b/2 trials in three high-value indications. Panna Sharma, CEO and President of Lantern Pharma, stated, “The third quarter represented a transformational period for Lantern as we announced successful enrollment completion of our LP-184 Phase 1a trial, achieving all primary endpoints with unique clinical benefit observations in multiple hard-to-treat solid tumors. The observed 48% clinical benefit rate at or above the therapeutic dose threshold, combined with the favorable safety profile and clear biomarker signals, validates our AI-driven, precision medicine approach and positions us to advance multiple planned high-value Phase 1b/2 trials.” In a significant regulatory milestone, Lantern held a Type C meeting with the U.S. Food and Drug Administration in September, which provided clear guidance on the development path for Starlight Therapeutics, its wholly owned subsidiary, in pediatric central nervous system (CNS) cancers, including Atypical Teratoid Rhabdoid Tumor (ATRT). The FDA offered supportive feedback on the proposed trial design, strengthening the regulatory pathway for this high-need indication. The company also made progress on other key programs. The Phase 2 HARMONIC™ trial for LP-300 continued enrollment and follow-up across sites in the U.S., Japan, and Taiwan. This trial evaluates LP-300 in combination with standard-of-care chemotherapy for never-smokers with NSCLC adenocarcinoma who have progressed after tyrosine kinase inhibitor therapy. At the 25th Annual Lymphoma, Leukemia & Myeloma (LL&M) Congress in October, Lantern presented clinical data from its LP-284 Phase 1 trial, showcasing a confirmed complete metabolic response in a heavily pretreated diffuse large B-cell lymphoma (DLBCL) patient. LP-284 has received multiple FDA Orphan Drug Designations and strong intellectual property protection, with composition of matter patents granted in the U.S., Europe, Japan, India, and Mexico, extending exclusivity through 2039. Lantern also demonstrated the commercial readiness of its RADR® platform at the inaugural AI for Biology and Medicine Symposium hosted by the University of North Texas in October. The company is rolling out a multi-agentic AI system focused on rare cancers, with a public launch planned for December 2025 and broader industry rollout expected in early 2026. Financially, Lantern reported cash, cash equivalents, and marketable securities of approximately $12.4 million as of September 30, 2025, down from $24.0 million at the end of 2024. The company expects its current capital will fund operations into approximately Q3 2026. R&D expenses decreased to $2.4 million in Q3 2025 from $3.7 million in the same period of 2024, driven by reduced clinical trial costs and payroll expenses. G&A expenses rose to $1.9 million due to increased investor relations and professional fees. The net loss for the quarter was $4.2 million, or $0.39 per share, compared to $4.5 million, or $0.42 per share, in Q3 2024. Lantern has entered into an ATM Sales Agreement with ThinkEquity LLC, authorizing sales of up to $15.5 million in common stock. During the quarter, the company raised $989,061 from the sale of 212,444 shares, with an additional $634,333 raised through October 2025. Looking ahead, the company anticipates key milestones in Q4 2025 and early 2026, including a KOL-hosted scientific webinar on November 20, 2025, to discuss LP-184 Phase 1a results, and a conference call on November 13, 2025, to review financial and operational updates.